The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: A global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

Matti Aapro, Ivo L Abraham, Carsten Bokemeyer, Heinz Ludwig, Karen MacDonald, Pierre Soubeyran, Matthew Turner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Goal: The benefit of supportive care with erythropoiesis-stimulating agents (ESAs) for patients with cancer-related anaemia is well known. However, the European Cancer Anaemia Survey (ECAS, data from 2001) showed that about 60% of cancer patients with anaemia do not receive any treatment. Since ECAS, evidence-based guidelines have provided recommendations for ESA use, but it is not known to what extent current treatment patterns follow these guidelines. To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described. Materials and methods: The A.C.T. study is a global, retrospective, pharmacoepidemiologic study of at least 2,560 medical records of anaemic patients with cancer who were previously treated with an ESA from a minimum of 186 centres. Records from patients aged greater than or equal to 18 years with a diagnosis of solid tumour or myeloma or lymphoma and who were started on ESAs 3-12 months before inclusion and followed for 8-10 weeks will be eligible. Factors associated with ESA non-responsiveness will also be evaluated. Main results: Completion of the European phase of the study is anticipated in late 2007 with the rest of the world closing in late 2007 or early 2008. Publication of findings is anticipated in 2008. Conclusions: By examining the extent to which anaemia management in clinical practice is congruent with best practice guidelines, the A.C.T. study will provide a further foundation for the development of evidence-based supportive cancer care.

Original languageEnglish (US)
Pages (from-to)193-200
Number of pages8
JournalSupportive Care in Cancer
Volume16
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Anemia
Retrospective Studies
Guidelines
Hematinics
Neoplasms
Therapeutics
Practice Guidelines
Medical Records
Publications
Lymphoma

Keywords

  • Anaemia
  • Cancer
  • Erythropoiesis-stimulating agent
  • Retrospective

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study : A global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. / Aapro, Matti; Abraham, Ivo L; Bokemeyer, Carsten; Ludwig, Heinz; MacDonald, Karen; Soubeyran, Pierre; Turner, Matthew.

In: Supportive Care in Cancer, Vol. 16, No. 2, 02.2008, p. 193-200.

Research output: Contribution to journalArticle

@article{3aff7c5ab0e84a1ba16fd3948f000a81,
title = "The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: A global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines",
abstract = "Goal: The benefit of supportive care with erythropoiesis-stimulating agents (ESAs) for patients with cancer-related anaemia is well known. However, the European Cancer Anaemia Survey (ECAS, data from 2001) showed that about 60{\%} of cancer patients with anaemia do not receive any treatment. Since ECAS, evidence-based guidelines have provided recommendations for ESA use, but it is not known to what extent current treatment patterns follow these guidelines. To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described. Materials and methods: The A.C.T. study is a global, retrospective, pharmacoepidemiologic study of at least 2,560 medical records of anaemic patients with cancer who were previously treated with an ESA from a minimum of 186 centres. Records from patients aged greater than or equal to 18 years with a diagnosis of solid tumour or myeloma or lymphoma and who were started on ESAs 3-12 months before inclusion and followed for 8-10 weeks will be eligible. Factors associated with ESA non-responsiveness will also be evaluated. Main results: Completion of the European phase of the study is anticipated in late 2007 with the rest of the world closing in late 2007 or early 2008. Publication of findings is anticipated in 2008. Conclusions: By examining the extent to which anaemia management in clinical practice is congruent with best practice guidelines, the A.C.T. study will provide a further foundation for the development of evidence-based supportive cancer care.",
keywords = "Anaemia, Cancer, Erythropoiesis-stimulating agent, Retrospective",
author = "Matti Aapro and Abraham, {Ivo L} and Carsten Bokemeyer and Heinz Ludwig and Karen MacDonald and Pierre Soubeyran and Matthew Turner",
year = "2008",
month = "2",
doi = "10.1007/s00520-007-0311-2",
language = "English (US)",
volume = "16",
pages = "193--200",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study

T2 - A global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

AU - Aapro, Matti

AU - Abraham, Ivo L

AU - Bokemeyer, Carsten

AU - Ludwig, Heinz

AU - MacDonald, Karen

AU - Soubeyran, Pierre

AU - Turner, Matthew

PY - 2008/2

Y1 - 2008/2

N2 - Goal: The benefit of supportive care with erythropoiesis-stimulating agents (ESAs) for patients with cancer-related anaemia is well known. However, the European Cancer Anaemia Survey (ECAS, data from 2001) showed that about 60% of cancer patients with anaemia do not receive any treatment. Since ECAS, evidence-based guidelines have provided recommendations for ESA use, but it is not known to what extent current treatment patterns follow these guidelines. To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described. Materials and methods: The A.C.T. study is a global, retrospective, pharmacoepidemiologic study of at least 2,560 medical records of anaemic patients with cancer who were previously treated with an ESA from a minimum of 186 centres. Records from patients aged greater than or equal to 18 years with a diagnosis of solid tumour or myeloma or lymphoma and who were started on ESAs 3-12 months before inclusion and followed for 8-10 weeks will be eligible. Factors associated with ESA non-responsiveness will also be evaluated. Main results: Completion of the European phase of the study is anticipated in late 2007 with the rest of the world closing in late 2007 or early 2008. Publication of findings is anticipated in 2008. Conclusions: By examining the extent to which anaemia management in clinical practice is congruent with best practice guidelines, the A.C.T. study will provide a further foundation for the development of evidence-based supportive cancer care.

AB - Goal: The benefit of supportive care with erythropoiesis-stimulating agents (ESAs) for patients with cancer-related anaemia is well known. However, the European Cancer Anaemia Survey (ECAS, data from 2001) showed that about 60% of cancer patients with anaemia do not receive any treatment. Since ECAS, evidence-based guidelines have provided recommendations for ESA use, but it is not known to what extent current treatment patterns follow these guidelines. To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described. Materials and methods: The A.C.T. study is a global, retrospective, pharmacoepidemiologic study of at least 2,560 medical records of anaemic patients with cancer who were previously treated with an ESA from a minimum of 186 centres. Records from patients aged greater than or equal to 18 years with a diagnosis of solid tumour or myeloma or lymphoma and who were started on ESAs 3-12 months before inclusion and followed for 8-10 weeks will be eligible. Factors associated with ESA non-responsiveness will also be evaluated. Main results: Completion of the European phase of the study is anticipated in late 2007 with the rest of the world closing in late 2007 or early 2008. Publication of findings is anticipated in 2008. Conclusions: By examining the extent to which anaemia management in clinical practice is congruent with best practice guidelines, the A.C.T. study will provide a further foundation for the development of evidence-based supportive cancer care.

KW - Anaemia

KW - Cancer

KW - Erythropoiesis-stimulating agent

KW - Retrospective

UR - http://www.scopus.com/inward/record.url?scp=38349187596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349187596&partnerID=8YFLogxK

U2 - 10.1007/s00520-007-0311-2

DO - 10.1007/s00520-007-0311-2

M3 - Article

C2 - 17874142

AN - SCOPUS:38349187596

VL - 16

SP - 193

EP - 200

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -